BioSpace News Archive

Soliton, Inc., (Nasdaq: SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today announced that the Company has received approval for the trial protocol from the independent Institutional Review Board (“IRB”) for its upcoming proof-of-concept fibrotic scar trial.

Inhibrx, Inc. (Inhibrx), a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates, announced today the enrollment of the first patient in a Phase 1 clinical trial of INBRX-101 (NCT03815396).

The Hyundai Hope On Wheels non-profit embarks on a nationwide tour this September to award new grants for pediatric cancer, surpassing $160 million in lifetime funding for research [04-September-2019] NEW YORK , Sept. 4, 2019 /PRNewswire/ -- Hyundai Hope On Wheels® (HHOW), a 501(c)(3) non-profit organization supported by Hyundai and its U.S. dealers, announces $300

Locana, a leading RNA-targeting gene therapy company, today announced the appointment of Kathie M. Bishop, Ph.D. as chief scientific officer.

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced the appointment of Peter Cohen, previously Lead Director, as Chairman of the Board.

ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces that it is scheduled to attend and / or present at the following investor and scientific conferences in September and October 2019.

Resonetics announced today that it has acquired Tru Tech Systems, Inc. (“Tru Tech”), based in Michigan, a leading supplier of precision grinding services for the medical device market and CNC grinding equipment for the machine tool industry

Tris Pharma, Inc. (“Tris”), a specialty pharmaceutical company with a robust portfolio of approved products and a late-stage pipeline of innovative product candidates for the treatment of Attention Deficit Hyperactivity Disorder and related disorders, announced the addition of two industry veterans to join its growing branded business

Sprout Pharmaceuticals (Sprout) announced today that the U.S. Food and Drug Administration (FDA) has removed their contraindication, or ban, on alcohol use with Addyi® (flibanserin), the first-and-only approved non-hormonal pill for acquired, generalized HSDD in premenopausal women.

Hoth Therapeutics, Inc. (Nasdaq: HOTH), a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from dermatological indications ranging from atopic dermatitis to chronic wound disorders, today issued a letter to shareholders.